Structure-activity relationships for substrate recognition by the human dopamine transporter

Biochemical Pharmacology

Volumn 67, Issue 2, 2004, Pages 293-302

  Appell, Michael ^a,d   Berfield, Janet L ^a,d   Wang, Lijuan C ^a   Dunn III, William J ^b   Chen, Nianhang ^a,e   Reith, Maarten E A ^a,c  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL CENTER FOR AGRICULTURAL UTILIZATION RESEARCH   (United States)

^e NEW YORK UNIVERSITY   (United States)

Author keywords

Cocaine antagonist; Dopamine carbonylation; Dopamine hydroxylation; Dopamine methylation; Dopamine recognition; Dopamine transport

Indexed keywords

1 NAPHTHALENE METHYLAMINE; 2 NAPHTHYLAMINE; 3 O METHYLDOPAMINE; 3,4 DIHYDROXYBENZYLAMINE; 3,4 DIHYDROXYPHENYLACETIC ACID; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 4 ETHOXYPHENOL; 4 ETHYLCATECHOL; 4 HYDROXYBENZYLCYANIDE; 4 HYDROXYPHENYLACETAMIDE; 4 HYDROXYPHENYLACETIC ACID; ACETAMIDE DERIVATIVE; ADRENALIN; AMINE; CATECHOL DERIVATIVE; COCAINE; CYANIDE; DEXAMPHETAMINE; DOPAMINE; DOPAMINE TRANSPORTER; N,N DIPROPYLDOPAMINE; NAPHTHALENE DERIVATIVE; NORADRENALIN; PHENOL DERIVATIVE; PHENYL GROUP; SEROTONIN; TYROSINE DERIVATIVE; TYROSINOL; TYROSOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALKYLATION; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CARBONYLATION; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; EMBRYO; HUMAN; HUMAN CELL; HYDROXYLATION; METHYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION;

EID: 1642457228     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.09.013     Document Type: Article

References (33)

1. Gainetdinov RR, Caron MG. Monoamine transporters: their role in maintaining neuronal homeostasis. In: Reith MEA, editor. Neurotransmitter transporters: structure, function, and regulation. Totowa, NJ: Humana Press; 2002. p. 171-92.
2. Rudnick G. Mechanisms of biogenic amine neurotransmitter transporters. In: Reith MEA, editor. Neurotransmitter transporters: structure, function, and regulation. Totowa, NJ: Humana Press; 2002. p. 25-52.
3. Horn AS. Characteristics of transport in dopaminergic neurons. In: Paton DM, editor. The mechanism of neuronal and extraneuronal transport of catecholamines. New York: Raven Press; 1976. p. 195-214.
4. Woodruff G.N., Watling K.J., Andrews C.D., Poat J.A., McDermed J.D. Dopamine receptors in rat striatum and nucleus accumbens conformational studies using rigid analogues of dopamine. J. Pharm. Pharmacol. 29:1977;422-427.
5. Meiergerd S.M., Schenk J.O. Striatal transporter for dopamine: catechol structure-activity studies and susceptibility to chemical modification. J. Neurochem. 62:1994;998-1008.
6. Chen N., Justice J.B. Differential effect of structural modification of human dopamine transporter on the inward and outward transport of dopamine. Brain Res. Mol. Brain Res. 75:2000;208-215.
7. Schömig E., Michael-Hepp J., Bonisch H. Inhibition of neuronal noradrenaline uptake (uptake1) and desipramine binding by N-ethylmaleimide (NEM). Naunyn Schmiedebergs Arch. Pharmacol. 337:1988;633-636.
8. 3H ]WIN 35,428 to the human dopamine transporter J. Neurochem. 72:1999;1095-1109.
9. 3H ]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane Mol. Pharmacol. 36:1989;518-524.
10. 3H ]WIN 35,428 binding to the dopamine uptake carrier. I. Effect of tonicity and buffer composition J. Neurosci. Methods. 51:1994;23-30.
11. Appell M., Dunn W.J. III, Reith M.E., Miller L., Flippen-Anderson J.L. An analysis of the binding of cocaine analogues to the monoamine transporters using tensor decomposition 3-d QSAR. Bioorg. Med. Chem. 10:2002;1197-1206.
12. Eshleman A.J., Stewart E., Evenson A.K., Mason J.N., Blakely R.D., Janowsky A., Neve K.A. Metabolism of catecholamines by catechol-O- methyltransferase in cells expressing recombinant catecholamine transporters. J. Neurochem. 69:1997;1459-1466.
13. - with the binding of amphetamine, octopamine, and tyramine to the human dopamine transporter. J. Neurochem. 74:2000;1538-1552.
14. Wang L.C., Berfield J.L., Kuhar M.J., Carroll F.I., Reith M.E. RTI-76, an isothiocyanate derivative of a phenyltropane cocaine analog as a tool for irreversibly inactivating dopamine transporter function in vitro. Naunyn Schmiedebergs Arch. Pharmacol. 362:2000;238-247.
15. DeLean A., Munson P.J., Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay and physiological dose-response curves. Am. J. Physiol. 235:1978;E97-102.
16. Simoni D., Stoelwinder J., Kozikowski A.P., Johnson K.M., Bergmann J.S., Ball R.G. Methoxylation of cocaine reduces binding affinity and produces compounds of differential binding and dopamine uptake inhibitory activity: discovery of a weak cocaine antagonist. J. Med. Chem. 36:1993;3975-3977.
17. Reith M.E.A., de Costa B., Rice K.C., Jacobson A.E. Evidence for mutually exclusive binding of cocaine, BTCP, GBR 12935, and dopamine to the dopamine transporter. Eur. J. Pharmacol. 227:1992;417-425.
18. 50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3099-3108.
19. Bonisch H. Transport and drug binding kinetics in membrane vesicle preparation. Methods Enzymol. 296:1998;259-278.
20. Christensen NH. Biological transport. London: W.A. Benjamin, Inc.; 1975. p. 113-9.
21. Zhang L., Coffey L.L., Reith M.E. Regulation of the functional activity of the human dopamine transporter by protein kinase. Biochem. Pharmacol. 53:1997;677-688.
22. + with the dopamine transporter: contribution by D313. Soc Neurosci Abstr 200228: #745.4.
23. Carroll FI, Lewin AH, Mascarella SW. Dopamine transporter uptake blockers. Structure-activity relationships. In: Reith MEA, editor. Neurotransmitter transporters: structure, function, and regulation. Totowa, NJ: Humana Press; 2002. p. 381-432.
24. 3H ]cocaine analog binding: a potential screening device for cocaine antagonists Methods Enzymol. 296:1998;248-259.
25. Uhl G., Lin Z., Metzger T., Dar D.E. Dopamine transporter mutants small molecules and approaches to cocaine antagonist/dopamine transporter disinhibitor development. Methods Enzymol. 296:1998;456-465.
26. Wang S., Sakamuri S., Enyedy I.J., Kozikowski A.P., Deschaux O., Bandyopadhyay B.C., Tella S.R., Zaman W.A., Johnson K.M. Discovery of a novel dopamine transporter inhibitor, 4-hydroxy-1-methyl-4-(4-methylphenyl)-3- piperidyl 4-methylphenyl ketone, as a potential cocaine antagonist through 3D-database pharmacophore searching. Molecular modeling, structure-activity relationships, and behavioral pharmacological studies. J. Med. Chem. 43:2000;351-360.
27. Fairhurst A.S., Whittaker M.L., Ehlert F.J. Interactions of D600 (methoxyverapamil) and local anesthetics with rat brain alpha-adrenergic and muscarinic receptors. Biochem. Pharmacol. 29:1980;155-162.
28. Huang L.M., Ehrenstein G. Local anesthetics QX 572 and benzocaine act at separate sites on the batrachotoxin-activated sodium channel. J. Gen. Physiol. 77:1981;137-153.
29. 3H ]WIN 35,428 binding Naunyn Schmiedebergs Arch. Pharmacol. 355:1997;64-73.
30. 3H ]WIN 35,428) binding Biochem. Pharmacol. 52:1996;1435-1446.
31. Ferrer J.V., Javitch J.A. Cocaine alters the accessibility of endogenous cysteines in putative extracellular and intracellular loops of the human dopamine transporter. Proc. Natl. Acad. Sci. U.S.A. 95:1998;9238-9243.
32. Reith M.E., Berfield J.L., Wang L.C., Ferrer J.V., Javitch J.A. The uptake inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter. J. Biol. Chem. 276:2001;29012-29018.
33. Chen N., Ferrer J.V., Javitch J.A., Justice J.B. Transport-dependent accessibility of a cytoplasmic loop cysteine in the human dopamine transporter. J. Biol. Chem. 275:2000;1608-1614.